60 filings
8-K
IMVT
Immunovant Inc
12 Feb 24
Results of Operations and Financial Condition
7:02am
8-K
IMVT
Immunovant Inc
9 Jan 24
Regulation FD Disclosure
8:08am
8-K
IMVT
Immunovant Inc
20 Dec 23
Immunovant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease
4:37pm
8-K
IMVT
Immunovant Inc
28 Nov 23
Immunovant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential
7:43am
8-K
IMVT
Immunovant Inc
9 Nov 23
Results of Operations and Financial Condition
7:06am
8-K
2bggvjj2 gcb
28 Sep 23
Entry into a Material Definitive Agreement
5:23pm
8-K
iotz807
26 Sep 23
Immunovant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results
7:45am
8-K
9vhn4doh451eutye
23 Aug 23
Submission of Matters to a Vote of Security Holders
4:48pm
8-K
sw1lpl
10 Aug 23
Results of Operations and Financial Condition
7:10am
8-K
fj8gqzgfdlait5m01v0
22 May 23
Results of Operations and Financial Condition
7:03am
8-K
5pc yimcvm
27 Mar 23
Other Events
7:07am
8-K
28p00xok81larwn2
3 Feb 23
Results of Operations and Financial Condition
7:05am
8-K
vt9 zy6l40
9 Jan 23
Other Events
8:38am
8-K
8k3ba4qnv315
8 Dec 22
Regulation FD Disclosure
7:06am
8-K
vgm72ehlbk
4 Nov 22
Results of Operations and Financial Condition
7:15am
8-K
c1few
4 Oct 22
Immunovant Announces Pricing of $75.0 Million Underwritten Offering of Common Stock
5:28pm
8-K
6dld4 s6fsnk
28 Sep 22
Immunovant Announces IMVT-1402, a Next Generation Anti-FcRn
10:49am
8-K
wlvi4w
7 Sep 22
Regulation FD Disclosure
6:39am
8-K
fy54zsmju3fug0
19 Aug 22
Submission of Matters to a Vote of Security Holders
5:01pm
8-K
zi1e3i5
5 Aug 22
Results of Operations and Financial Condition
7:07am